Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

View Full Paper
Ask AI
Bookmark
Share

Authors

TVTimothy VoorheesEBEvandro D. BezerraDBDavid A. Bond

Discussion

Loading...

Member takes

Overview

Observational analysis shows similar clinical outcomes for response rates and survival in non-Hodgkin's lymphoma patients with and without autoimmune disease, highlighting shared treatment efficacy.

Key Points

  • Response rates and survival outcomes remained similar for patients with autoimmune disease and those without.
  • The overall response rate for patients lacking autoimmune diseases was 65.5%, compared to 66.6% with autoimmune conditions.
  • Chimeric antigen receptor T-cell therapy was utilized to evaluate clinical outcomes in a retrospective analysis of patients.
  • Lower severity of immune effector cell associated neurotoxicity syndrome was noted in patients with autoimmune diseases; further work required.

Cite This Study

Voorhees et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5a5https://doi.org/10.1182/blood-2025-1935
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune recovery and immunologic remodeling after CD19-directed chimeric antigen receptor T cell therapy in autoimmune diseases2025
  2. 2Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience2025
  3. 3Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies2025
  4. 4Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience2025 · 1 citations
  5. 5Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study2025